
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a promising company in the biotech industry with a strong focus on developing cannabinoid-based formulations for the treatment of diseases such as Alzheimer's. The company has achieved over 70% patient enrollment in their Phase 2 CALMA trial and reported positive interim results for their investigational drug, IGC-AD1, which has shown potential in suppressing key hallmarks of Alzheimer's disease. The company also has a strong pipeline with 5 novel therapeutic drug candidates for Alzheimer's disease, and their CEO recently presented upcoming milestones. With a current attractive valuation and potential for significant upside opportunities, the company has a positive outlook for the future, although risks such as balance sheet and liquidity risks, regulatory approvals and competition should be considered.
Bears say
IGC Pharma is expected to report its fiscal Q3 2026 results in early March, with expected revenue of $0.2 million and EPS of $(0.02). The company also has a recent change in FYE and reported positive interim results for its Phase 2 trial for IGC-AD1 as a treatment for agitation in Alzheimer's patients. Despite a large market potential, the company's minimal revenue and lack of a known cure for Alzheimer's make it a risky investment opportunity.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares